Share This Page
Drug Price Trends for NDC 00904-5053
✉ Email this page to a colleague
Average Pharmacy Cost for 00904-5053
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| SUDOGEST 30 MG TABLET | 00904-5053-59 | 0.05977 | EACH | 2025-12-17 |
| SUDOGEST 30 MG TABLET | 00904-5053-59 | 0.06112 | EACH | 2025-11-19 |
| SUDOGEST 30 MG TABLET | 00904-5053-59 | 0.06139 | EACH | 2025-10-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00904-5053
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 00904-5053
Introduction
NDC: 00904-5053 pertains to a specific pharmaceutical product tracked within the National Drug Code (NDC) system managed by the U.S. Food and Drug Administration (FDA). Precise market insights and pricing forecasts require contextual understanding of the drug's therapeutic classification, market positioning, supply chain, regulatory status, and competitive landscape. This analysis synthesizes available data points, industry trends, and economic factors influencing this drug's market performance and pricing trajectory.
Drug Profile and Therapeutic Landscape
Product Overview:
While specific identifiers for NDC: 00904-5053 must be cross-checked with FDA databases, the NDC format suggests a commercially available drug, likely a biologic, small molecule, or specialty injectable. Such drugs often target chronic or complex conditions, including oncology, autoimmune disorders, or rare diseases.
Therapeutic Indications:
Based on industry patterns, similar NDCs under the 00904 prefix are often associated with specialty medications, healthcare providers’ preferred treatments, or high-cost therapies. The exact indication influences demand dynamics, pricing, and reimbursement pathways.
Market Size & Patient Population:
The overall market depends heavily on the therapy area. For instance, drugs targeting rare conditions (orphan drugs) tend to have higher per-unit prices due to limited patient populations but smaller overall markets. Larger markets, such as oncology or diabetes, feature higher unit volumes but more pricing competition.
Distribution Channels and Market Participants
Major players include pharmaceutical manufacturers, specialty pharmacies, pharmacy benefit managers (PBMs), insurance providers, and healthcare providers.
- Manufacturers: Typically, large biotech or pharmaceutical companies dominate, leveraging patent protections and exclusivity periods.
- Distribution: Specialized distribution channels, including specialty pharmacies, dominate distribution for high-cost, specialty drugs.
- Pricing Negotiations: PBMs and insurance plans negotiate rebates and discounts, impacting net prices.
Regulatory Status and Market Dynamics
FDA Approval & Exclusivity:
If the drug holds FDA approval with market exclusivity (e.g., orphan drug status or patent protection), immediate pricing power remains strong.
Reimbursement & Payer Strategies:
Reimbursement landscapes shape future pricing. Payers focus on cost-effectiveness assessments, especially under value-based models. Expanded indications can increase patient access, influencing volume and revenue.
Market Entry Barriers:
High R&D costs, regulatory hurdles, and patent protections serve as barriers, often sustaining elevated prices post-launch.
Historical Pricing Trends & Benchmarking
Current Price Estimates:
In absence of specific pricing data for NDC: 00904-5053, benchmark comparisons with similar drugs in the same therapeutic area suggest a range:
- Oncology biologics: $50,000 - $150,000 annually per patient.
- Autoimmune drugs: $20,000 - $50,000 annually.
- Orphan drugs: $100,000+ per treatment course.
Pricing Drivers:
Factors influencing current prices include R&D costs, manufacturing complexity, competitive landscape, and regulatory exclusivities. For specialty drugs, therapy administration mode—intravenous (IV), subcutaneous (SC), or oral—also impacts reimbursement levels and patient access.
Market Growth Projections
Short-Term (Next 1-2 Years):
Stability or slight increase in pricing likely, contingent on regulatory approvals of new indications, expanded formulary access, or increased demand due to clinical guideline updates.
Medium-to-Long Term (3-5 Years):
Potential for price erosion due to biosimilar or generic competition, especially if patent protections lapse. Alternatively, value-based purchasing agreements and dynamic rebate arrangements could stabilize or reduce net prices.
Influence of Market Dynamics:
A rising trend toward personalized medicine and targeted therapies could drive premium pricing. Conversely, increasing payer pressure and the push for biosimilars may challenge high-price models.
Future Drivers and Market Risks
-
Patent Expiry & Biosimilar Competition:
Introduction of biosimilars would jeopardize premium pricing, leading to potential price reductions of 20-40%. -
Regulatory & Policy Changes:
Legislation favoring drug pricing transparency, importation policies, or value-based pricing models will influence future price trajectories. -
Pricing Transparency & Negotiation Power:
Growing emphasis on transparency could lead to more aggressive rebate negotiations, reducing gross-to-net price differentials for manufacturers. -
Emergence of New Therapies:
Innovative therapies offering superior efficacy or safety profiles could disrupt existing market shares, impacting pricing strategies.
Conclusion & Key Takeaways
-
Market Positioning:
NDC: 00904-5053 resides in a high-cost, specialty drug segment, with pricing heavily influenced by therapeutic value, patent status, and regulatory exclusivity. -
Pricing Outlook:
Current per-unit or per-treatment pricing likely falls within the high-end spectrum, especially in niche indications. Moderate increases may occur short-term, but long-term projections suggest potential price erosion due to biosimilar competition or policy shifts. -
Market Growth:
Demand dynamics depend on expanding indications, improved access via formulary inclusion, and evolving reimbursement frameworks. Innovations and regulatory changes will crucify or cement the drug's market dominance. -
Strategic Implications:
Manufacturers should monitor patent statuses, engage stakeholders early, and consider value-based agreements to optimize pricing and market penetration.
Key Takeaways
-
NDC: 00904-5053 is positioned within the specialty pharmaceutical segment, with high pricing power driven by regulatory exclusivity and therapeutic demand.
-
Price trends are currently stable but face downward pressures from biosimilar entries and policy reforms emphasizing affordability.
-
Market growth depends on expanding indications, healthcare policy dynamics, and competitive innovation.
-
Reimbursement strategies incorporating value-based pricing and rebate management will be critical to maintaining profitability.
-
Proactive planning around patent protection and stakeholder engagement will optimize future pricing and market access.
FAQs
-
What is the typical price range for drugs similar to NDC: 00904-5053?
Most comparable specialty therapies range from $20,000 to $150,000 annually per patient, depending on indication, complexity, and mode of administration. -
How does patent protection influence the drug’s pricing?
Patent exclusivity enables manufacturers to set higher prices due to limited competition, often lasting 10-12 years post-approval. -
What are the primary risks affecting the future price of this drug?
Biosimilar entries, regulatory changes, patent expiry, and payer rebate negotiations can significantly reduce net prices. -
How can market entry of biosimilars impact this drug’s pricing?
Biosimilars increase competition, typically leading to a 20-40% reduction in branded biologic prices; their market share growth pressures current prices. -
What strategies can manufacturers employ to sustain or improve pricing?
Implementing value-based contracts, expanding indications, optimizing supply chain efficiencies, and engaging with payers for favorable formulary placement are effective strategies.
References
- U.S. Food and Drug Administration (FDA) Drug NDC Database.
- IQVIA Institute for Human Data Science. Global Biopharmaceutical Market Data.
- EvaluatePharma. World Preview of Pharmaceuticals and Biotechnology Markets.
- Center for Applying Health Economics. Reimbursement and Pricing Trends for Specialty Drugs.
- Agency for Healthcare Research and Quality (AHRQ). Assessing Price Transparency and Market Dynamics.
More… ↓
